Literature DB >> 2783335

Establishment of two interleukin 6 (B cell stimulatory factor 2/interferon beta 2)-dependent human bone marrow-derived myeloma cell lines.

S Shimizu1, R Yoshioka, Y Hirose, S Sugai, J Tachibana, S Konda.   

Abstract

Two IL-6-dependent human multiple myeloma cell lines, ILKM2 and ILKM3, were established from the bone marrow of patients with IgG-K multiple myeloma. Both cell lines had the typical morphology and immunocytochemical features of myeloma cells. The surface phenotype of both cell lines was PCA-1+, OKT10+, CD10(J-5)-, CD19(B4)-, CD20(B1)-, CD21(B2)-, and OKIa-1-. A monoclonal cytoplasmic Ig, IgG-K or K L chain, was positive in ILKM2 or ILKM3, respectively. EBV nuclear antigen was negative in both cell lines. They proliferated in the presence of macrophages or macrophage-derived factors (MDF). Among the recombinant cytokines examined, IL-6 most strongly augmented the growth of both cell lines. The anti-IL-6 antibody completely inhibited the IL-6-dependent growth and almost completely inhibited the MDF- or purified MDF-dependent growth of both cell lines, ILKM2 and ILKM3 are now being maintained in the culture medium containing 2 ng/ml rIL-6. These results suggest that IL-6 produced by macrophages may play an important role in the growth of myeloma cells in vivo and that macrophages or IL-6 can be used for establishing human myeloma cell lines.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2783335      PMCID: PMC2189192          DOI: 10.1084/jem.169.1.339

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  18 in total

1.  Production of free light chains of immunoglobulin by a hematopoietic cell line derived from a patient with multiple myeloma.

Authors:  Y Matsuoka; G E Moore; Y Yagi; D Pressman
Journal:  Proc Soc Exp Biol Med       Date:  1967 Aug-Sep

2.  Establishment and characterization of a human plasma cell myeloma culture having a rearranged cellular myc proto-oncogene.

Authors:  A F Gazdar; H K Oie; I R Kirsch; G F Hollis
Journal:  Blood       Date:  1986-06       Impact factor: 22.113

3.  A macrophage-derived factor required by plasmacytomas for survival and proliferation in vitro.

Authors:  R P Nordan; M Potter
Journal:  Science       Date:  1986-08-01       Impact factor: 47.728

4.  Immunocytology of cultured IgM-forming cells of mouse. I. Requirement of phagocytic cell factor for the growth of IgM-forming tumor cells in tissue culture.

Authors:  Y Namba; M Hanaoka
Journal:  J Immunol       Date:  1972-12       Impact factor: 5.422

5.  Interleukin-6 (B-cell stimulatory factor 2)-dependent growth of a Lennert's lymphoma-derived T-cell line (KT-3).

Authors:  S Shimizu; T Hirano; R Yoshioka; S Sugai; T Matsuda; T Taga; T Kishimoto; S Konda
Journal:  Blood       Date:  1988-11       Impact factor: 22.113

6.  Absence of antiviral activity in recombinant B cell stimulatory factor 2 (BSF-2).

Authors:  T Hirano; T Matsuda; K Hosoi; A Okano; H Matsui; T Kishimoto
Journal:  Immunol Lett       Date:  1988-01       Impact factor: 3.685

7.  Structure and expression of cDNA and genes for human interferon-beta-2, a distinct species inducible by growth-stimulatory cytokines.

Authors:  A Zilberstein; R Ruggieri; J H Korn; M Revel
Journal:  EMBO J       Date:  1986-10       Impact factor: 11.598

8.  The requirement of an adherent cell substratum for the growth of developing plasmacytoma cells in vivo.

Authors:  M Cancro; M Potter
Journal:  J Exp Med       Date:  1976-12-01       Impact factor: 14.307

9.  Identification of the human 26-kD protein, interferon beta 2 (IFN-beta 2), as a B cell hybridoma/plasmacytoma growth factor induced by interleukin 1 and tumor necrosis factor.

Authors:  J Van Damme; G Opdenakker; R J Simpson; M R Rubira; S Cayphas; A Vink; A Billiau; J Van Snick
Journal:  J Exp Med       Date:  1987-03-01       Impact factor: 14.307

10.  Long-term establishment of a human plasmacyte cell line derived from a patient with IgD multiple myeloma. I. Requirement of a plasmacyte-stimulating factor for the proliferation of myeloma cells in tissue culture.

Authors:  M E Jobin; J L Fahey; Z Price
Journal:  J Exp Med       Date:  1974-08-01       Impact factor: 14.307

View more
  21 in total

1.  Point mutation in codon 61 of N-RAS genes in human myeloma cell lines.

Authors:  M Sawada; S Shimizu; T Arai; S Konda; N Enomoto; T Date
Journal:  Nucleic Acids Res       Date:  1989-11-11       Impact factor: 16.971

Review 2.  Interleukin-6 and the acute phase response.

Authors:  P C Heinrich; J V Castell; T Andus
Journal:  Biochem J       Date:  1990-02-01       Impact factor: 3.857

Review 3.  Tutorial: guidelines for annotating single-cell transcriptomic maps using automated and manual methods.

Authors:  Zoe A Clarke; Tallulah S Andrews; Jawairia Atif; Delaram Pouyabahar; Brendan T Innes; Sonya A MacParland; Gary D Bader
Journal:  Nat Protoc       Date:  2021-05-24       Impact factor: 13.491

Review 4.  Viewpoint on the impact of interferon in the treatment of multiple myeloma: benefit for a small proportion of patients?

Authors:  J Bladé; J Esteve
Journal:  Med Oncol       Date:  2000-05       Impact factor: 3.064

5.  Tumor necrosis factor is a survival and proliferation factor for human myeloma cells.

Authors:  M Jourdan; K Tarte; E Legouffe; J Brochier; J F Rossi; B Klein
Journal:  Eur Cytokine Netw       Date:  1999-03       Impact factor: 2.737

6.  A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells.

Authors:  Michel Jourdan; Jean-Luc Veyrune; John De Vos; Nicole Redal; Guilhem Couderc; Bernard Klein
Journal:  Oncogene       Date:  2003-05-15       Impact factor: 9.867

7.  Serum concentrations of interferon gamma, interleukin-6 and neopterin in patients with infectious mononucleosis and other Epstein-Barr virus-related lymphoproliferative diseases.

Authors:  V Schuster; M Herold; H Wachter; G Reibnegger
Journal:  Infection       Date:  1993 Jul-Aug       Impact factor: 3.553

8.  Interleukin-6 functions as an intracellular growth factor in hairy cell leukemia in vitro.

Authors:  B Barut; D Chauhan; H Uchiyama; K C Anderson
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

9.  Interleukin-7 (IL-7)-induced proliferation of CD8+ T-chronic lymphocytic leukemia cells.

Authors:  R Yoshioka; S Shimizu; J Tachibana; Y Hirose; M Fukutoku; Y Takeuchi; S Sugai; T Takiguchi; S Konda
Journal:  J Clin Immunol       Date:  1992-03       Impact factor: 8.317

10.  Frap, FKBP12 rapamycin-associated protein, is a candidate gene for the plasmacytoma resistance locus Pctr2 and can act as a tumor suppressor gene.

Authors:  Valery Bliskovsky; Edward S Ramsay; John Scott; Wendy DuBois; Wei Shi; Shuling Zhang; Xiaolan Qian; Douglas R Lowy; Beverly A Mock
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-21       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.